CervoMed is trading at $2.80, with a -13.04% change; no clearly linked new company announcement was identified to explain the decline.
- CervoMed was scheduled to present Phase 2a biomarker results at an October 11 conference, but available reporting does not establish that the presentation caused the October 12 decline.
- Healthcare was up 1.58% pre-market, so sector strength does not explain the move lower.
- No trading-volume evidence was available.